Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
PHAGO logo


Start Date
End Date
IMI2 - Call 5
Grant agreement number

IMI Funding
8 838 000
EFPIA in kind
9 092 496
Total Cost17 930 496


Clumps of proteins in the brain called amyloid plaques are a hallmark of Alzheimer’s disease, and very often specialised immune cells cluster around these plaques. Recent research has shown that two genes involved in the immune system, TREM2 and CD33, appear to be involved in this immune response to Alzheimer’s disease and could therefore be targets for drugs. However, their exact role in the disease is still poorly understood. The PHAGO project aims to develop tools and methods to study the workings of these genes. The project results will therefore pave the way for the development of novel drugs that could tackle Alzheimer’s disease via this route.

Participants Show participants on map

EFPIA companies
  • AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
  • AstraZeneca AB, Södertälje, Sweden
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • H. Lundbeck A/S, Valby, Denmark
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Orion Corporation, Espoo, Finland
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Charité – Universitätsmedizin Berlin, Berlin, Germany
  • Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V., Bonn, Germany
  • Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany
  • Goeteborgs Universitet, Gothenburg, Sweden
  • King's College London, London, United Kingdom
  • Universitaetsklinikum Bonn, Bonn, Germany
  • University College London, London, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arttic , Paris, France
  • Axxam SpA, Bresso (Milan), Italy
  • Life & Brain GMBH, Bonn, Germany


Project leader
Dr. Andreas Ebneth
Janssen Pharmaceutica NV
Project coordinator
Harald Neumann
Universitaetsklikum Bonn
E-mail address